<DOC>
	<DOCNO>NCT02351427</DOCNO>
	<brief_summary>The purpose study determine whether bortezomib effective treatment acute cellular rejection kidney transplantation .</brief_summary>
	<brief_title>Bortezomib With Steroid Pulse Therapy Acute Cellular Rejection Kidney Transplantation</brief_title>
	<detailed_description>When acute cellular rejection occur kidney allograft , investigator administer high dose steroid . However , insufficient effect 20-30 % . Bortezomib act plasma cell , also T cell , B cell dendritic cell . In addition , bortezomib relatively safe drug compare thymoglobulin investigator use case steroid failure . Therefore , investigator administer bortezomib steroid one group , compare group group conventional steroid treatment do .</detailed_description>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>live donor kidney transplantation recipient patient perform kidney biopsy laboratory clinically suspect rejection Biopsy proven acute cellular rejection ( Banff I IIA ) C4d negative Single luminex panel reactive antibody ( PRA ) I &amp; II mean fluorescent intensity ( MFI ) &lt; 3000 patient receive major organ transplantation combine urinary tract infection obstruction combine acute antibody mediate rejection poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>